Stock Comparison

ABBV vs BEAM

AbbVie Inc vs Beam Therapeutics Inc

The Verdict

BEAM takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

BEAM

Beam Therapeutics Inc

9.4

out of 10

Hidden Gem

Head-to-Head

$381.1B

Market Cap

$3.2B

104.8

P/E Ratio

-5.2

5.8%

Profit Margin

-39.7%

95.6%

Return on Equity

-5.9%

20.2

Debt-to-Equity

0.2

Moderate

Overall Risk

Aggressive

0.1

DVR Score

9.4

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

BEAM9.4/10

Beam Therapeutics retains exceptionally high 10x growth potential, driven by its proprietary base editing platform, which continues to promise precision genetic cures. The recent Q1 2026 earnings report (May 7, 2026) provided critical clarity, showing a robust cash position of $1.2B against only $100M in debt, significantly de-risking financial runway concerns. Revenue surged +323% YoY, and EPS im...

Full BEAM Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.